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ABSTRACT 
TNF-a is an important cytokine mediator of inflammation which suggests that inhibition 
of TNF-a activity may provide potential for clinical application. Recent data indicated that 
treatment of both human and mouse cells with Kavain significantly modulates P. 
gingivalis- and LPS-induced TNF-α expression. In order to obtain a selective analog with 
optimized biological activity and structural physico-chemical properties of Kavain, Kavain 
analogs were designed and synthesized and found one Kavain analogue (named Kav001) 
that is similar to Kavain but soluble and does not induce a significant toxicity. Both studies 
in vitro and in vivo treatment by Kav001 showed stronger biological function as compared 
to Kavain. Furthermore, most mouse bone marrow macrophages up-regulated Bcl-6 while 
down-regulating LITAF expression after treatment with Kav001 for 36 h. Consequently, 
this led to an extension of macrophage pseudopods due to its immune response to P.g. 
infection/ LPS stimulation. we further found that Kav001 not only inhibits TNF-α, but also 
IL-1β, IL-6, caspase 1 and neutrophil infiltration in response to LPS. However, this 
phenomenon cannot be observed when macrophages were treated with LPS plus Kavain. 
We believe that Kav001 may mediate a novel link between Kav001 and LPS-induced 
  vi 
inflammation and may be used as a key inhibitor to LPS-induced 
inflammation/inflammatory disease. 
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INTRODUCTION 
Periodontal diseases and Inflammation 
      Periodontal diseases are the term including all the diseases that affect the  periodontium 
(1). Periodontal diseases are inflammatory in nature and mostly induced by bacteria leading 
to tissue destruction (2). An imbalanced relationship between the host and the bacteria 
leads to the disease stage (3). Early discoveries on how to treat them and the structures 
themselves have been made in ancient times by the Chinese and the Egyptians (1). 
 
FIGURE 1: The root is held within the alveolar bony by the attachment structures of the 
periodontium. The gingiva (G) and alveolar mucosa (M) cover the attachment structures 
of alveolar bone (AB), periodontal ligament (PDL), and tooth- root cementum as 
described (1). 
     Different microbial complexes live in the periodontium and each complex has a 
unique characteristic that plays a role in the pathogenesis process. As shown in figure 2, a 
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diagram of the relationships among 40 bacterial species detected in 4475 supragingival 
biofilm samples from 187 subjects at baseline was presented. The figure is based on 
cluster analyses that employed nine similarity coefficients de-scribed in the Materials and 
methods section as well as two community ordination techniques: principal components 
analysis and correspondence analysis (4). P.gingivalis, which is an anaerobic gram 
negative bacterium, is considered to be one of major bacteria living in the mouth that 
causes periodontal disease (5). 
 
FIGURE 2: Diagrammatic representation of the relationships of species within microbial 
complexes and between the microbial complexes in supra gingival biofilm samples. This 
diagram was based on the results of nine cluster and two community ordination analyses 
using the baseline data from 187 subjects as described (4). 
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      A United States national survey was conducted to determine the prevalence and 
distribution of one of the periodontal diseases initiated from gingivitis that started from 
early childhood, with a range between 40% to 60% in school children. From the survey in 
1963-65, the results from this survey of dental health ranged from 6-11-year-old children 
(6, 7), 
 
 
FIGURE 3: Average Periodontal index for children by age and race as described (8). 
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      For adults with gingivitis, the National Institute of Health found that 47% of males and 
39% of females have gingivitis (9). In addition, periodontitis was found in 30% of the 
United States population (10, 11). 
 
FIGURE 4: US adults without gingivitis or periodontitis as described (National Institute 
of Dental 1987). 
 
       Recent study confirms that near 50% of the United States have periodontitis (12, 13). 
To comprehend the impact of the periodontal diseases, exploring the correlation between 
periodontal diseases and systemic diseases is necessary. An interaction between different 
systemic diseases along with some risk factors like smoking were established (14, 15). 
Treatment of periodontitis were found to influence the inflammation profile of the systemic 
inflammatory diseases (16). Presence and severity of diabetes strongly affect periodontitis 
severity (15). Furthermore, periodontal diseases is a high risk factor for cardiovascular 
disease (8). 
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FIGURE 5: Proposed mechanisms linking periodontitis and cardiovascular disease 
(CVD) as described (Kholy, Genco et al. 2015). 
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FIGURE 6: Schematic representation of the proposed two-way relationship between 
obesity, diabetes and periodontitis as described (15). 
 
     Any disturbance to the balanced status between the microbiome and the host cells leads 
to the increasing number of bacteria, which causes tissue destruction and inflammatory 
reaction. The role of dental plaque is essential for gingivitis and periodontitis (17). The 
host defense responds to the microbial invasion by promoting initial inflammatory cell 
infiltration, which is clinically shown by plaque formation and gingival bleeding. The 
whole gingivitis and periodontitis disease stages is divided into four stages that ends by 
irreversible attachment and bone loss (18). 
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FIGURE 7: Overview of the molecules and cells involved in the disease and immune 
response as described (Cekici, Kantarci et al. 2014). 
 
    Cytokines are proteins with low molecular weight involved in several aspects of cell 
signaling, including the inflammation process. They are produced mainly by neutrophils, 
resident cells and macrophages (18). There are many inflammatory cytokines that induce 
the inflammatory and pathogenesis process including TNF-α and IL-1β (19).   
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FIGURE 8: IL-1𝛽𝛽 associated intracellular signaling pathways and downstream cellular 
targets and effects as described (19). 
 
      According to a meta-analysis, TNF-a was found to play a major role in increasing the 
probability of periodontitis (20). Higher levels of IL-1β and IL-6 and other cytokines in the 
gingival crevicular fluid were proposed as valid inflammatory bio-markers (21, 22). 
Cytokine pathways also regulated the host immune system (18). Significant decreases in 
IL-1β, IL-8 and MMP-8 resulted in improved clinical outcomes following scaling and root 
planning in subjects with periodontitis (23).  
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FIGURE 9: Correlations between amounts of IL-1β, IL-8 and MMP-8 in gingival 
crevicular fluid and clinical parameters in healthy control subjects and in chronic 
periodontitis patients at baseline and 1 and 4 wks. after scaling and root planning 
treatment as described (23). 
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Current chemical therapeutic approaches including development of Kavain: 
     Different chemical compounds were introduced to treat periodontal diseases. The main 
periodontal disease chemical therapy is antibiotics. Systemic antibiotics are currently 
considered to be the best choice in treating periodontal diseases, or if the other choices of 
therapy did not achieve the desired outcome (24). It is mostly found to be beneficial when 
it is used in combination with mechanical or surgical therapy as an anti-microbial agent 
(25). On the other hand, antibiotics have concerning disadvantages such as increased 
microbial resistance, allergies (ex. Penicillin), side effects and drug interactions (26). Other 
chemical compounds such as Chlorohexidine and Listerine were used as mouth rinses to 
treat and control gingivitis (27). Essential oils were also found to add some benefit when 
used in mouth rinses for reducing plaque and gingivitis. As shown in figure 10, the levels 
of gingivitis MGI and GI at baseline and end trial in the test and control groups were 
displayed (28). 
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FIGURE 10: Gingivitis data for the studies using EO rinse. Forest plot demonstrating 
baseline and end values for MGI and GI. The size of the box signifies the “weight” or 
importance of the study. WMDs between test and control groups are provided, including 
the 95% CIs in parentheses. Corresponding study numbers are shown in brackets.as 
described (Stoeken, Paraskevas et al. 2007). 
 
      Based on the data describing the importance of inflammatory cytokines, targeting these 
cytokines to suppress inflammation introduced several studies exploring this approach by 
experimenting different anti-cytokine treatments. IL-6 is another cytokine that has been 
targeted therapeutically in RA. Tocilizumab, a humanized monoclonal antibody targeting 
the IL-6 receptor (IL-6R) α protein in its soluble and membrane-bound forms, is currently 
the only anti–IL-6 agent licensed for the treatment of RA. A schematic of the mechanism 
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of action of tocilizumab is shown in Fig. 11 and compared with other non-TNF biologics 
approved for the treatment of RA. (29). 
 
 
FIGURE 11: Non-TNF biologic agents approved for the treatment of rheumatoid arthritis. 
Schematic outlining the main binding sites and mechanisms of the biologic agents other 
than TNF inhibitors approved for the treatment of RA. Abatacept is a fusion protein of the 
extracellular domain of CTLA-4 and the Fc region of IgG1. Rituximab is a chimeric 
monoclonal antibody targeting the protein CD20. Anakinra is a recombinant version of 
human IL-1Ra. Tocilizumab is a humanized monoclonal antibody targeting the IL-6 
receptor α protein. APC, antigen presenting cell; MHC, major histocompatibility complex; 
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; TCR, T-cell receptor (Siebert, 
Tsoukas et al. 2015). 
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       Modulating inflammatory cytokines like IL-ß and TNF-a protected the periodontium 
in a P.g induced rat periodontitis model by an antimicrobial novel compound (30). Kavain 
was one of promising choices for suppressing TNF-a production leading us to consider 
Kavain as an efficient anti-inflammatory treatment. The major constituents of kava are 
styryl α-pyrones generally referred to as kavalactones below. The six major kavalactones 
are the enolides kavain (1), methysticin (2), and their dihydro derivatives reduced in the 
cinnamyl side-chain, dihydrokavain (3) and dihydromethysticin (4) and the dienolides 
yangonin (5) and demethoxy-yangonin (6). Kava also contains, in smaller amounts, the 
chalcones flavokavain A (7), flavokavain B (8), and flavokavain C (9), as well as traces of 
the piperidine alkaloids pipermethysticine and awaine (31).  
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FIGURE 12. Major components of Kava 
       A study demonstrated the ability of Kavain to reduce TNF-a production in cells in 
addition to other advantages like oral bioavailability (32). A recent study found that Kavain 
inhibited E. coli LPS-induced TNF-a secretion (33). Furthermore, Kavain was also found 
to be involved in inflammation signaling pathways (34). Cytokines are proteins secreted 
by different cells with a role of transporting specific signals that control the host immune 
response (35). Their main function is to regulate the immune response both in the innate 
and adaptive immune systems (36). They were first described in the 1960s (37, 38) and 
Inflammatory cytokines important role of controlling diseases with inflammatory nature 
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have been widely researched and explored (19, 39, 40). The levels of the cytokines were 
found to be correlated directly with severity and degree of the inflammation (41). The 
stimulation process is induced by bacterial effect along with other factors (42). The effect 
of cytokines could be inflammatory or anti-inflammatory based on their function, 
characteristics and type (43). This dual effect introduced the idea of experimenting with 
different approaches to control cytokine production levels to achieve the anti-inflammatory 
outcome (36, 44). A number of anti-cytokine therapeutic agents showed significant 
antitumor properties (45). Additionally, anti-cytokines were also found to be effective in 
several inflammatory diseases (29). A novel antimicrobial treatment resulted in preventive 
outcome with P.gingivalis induced periodontitis in a rat model by regulating the production 
of pro-inflammatory cytokines like TNF-alpha and IL-1b (30). 
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Kavain extract from Kava Plant 
      Kava is a plant found in the South Pacific Islands and it has been used for recreational 
and therapeutic purposes for a long time (46). Kava is used as a stimulating beverage in 
ceremonies by the South Pacific Islanders (47). The scientific name of the Kava plant is 
Piper methysticum (48). Kava is also known as intoxicating pepper, Kavain and Kawa 
(49). 
 
FIGURE 13: Most famous kava names as described (Wooltorton 2002). 
Kava became more recognized after 1990 ((50) and was noted for it is therapeutic 
properties (51). The effective ingredient in the Kava plant is extracted from the root trunk 
(52). 
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A group of active components of the Kava extract has a structure of a related lipophilic 
derivatives plus an aryl-ethylene-a-pyrone framework with more than 18 products known 
as kavalactones (53). For example, Kavain (11.5%), dihydroKavain (13.5%), 
dihydromithysticin (10%) are some of the major components of the Kava (54), 
 
 
FIGURE 14: The major components of kava. The relative abundance of the major 
constituents are shown in parenthesis as described (54). 
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and they are responsible for approximately 96% of biological activity (50). Various 
techniques are used to extract Kava, including water, alcohol, liquid carbon dioxide and 
acetone extraction techniques (55). A study compared differences in efficiency between 
several Kava extract solvents like ethanol, methanol and acetone in which ethanol was the 
most efficient solvent (47).  
       Kavain, as one of the major active kavalactones, gained interest by researchers for its 
therapeutic potential. A study suggested that Kavain at certain concentrations can inhibit 
Na+ channels and down regulate Ca2+ channels on mammalian presynaptic nerve endings 
(56).  
 
 
FIGURE 15: Effect of kavain on veratridine- and monensin-induced increase in [Ca2+]i 
and glutamate-release as described (56). 
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Another study concurs with the previous mentioned study of the ability of Kavain of 
reducing the Na+ and Ca2+ channel currents of dorsal ganglion cells in neonatal rats, 
indicating anticonvulsive and analgesic properties of Kavain (57). 
 
 
FIGURE 16: Slow reduction of voltage-dependent CA2+ and NA+ as described 
(Schirrmacher, Busselberg et al. 1999). 
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     A study investigated Kavain effects toward sleeping and hypnosis, and concluded that 
Kavain causes hypnotic effects and enhances sleep quality (58). A Cochrane review was 
conducted to evaluate Kavain’s safety and potency for treating anxiety. The conclusion 
was that Kavain is indeed an effective treatment for anxiety (59). 
 
 
FIGURE 17: Comparison between kava and placebo on anxiety as described (Pittler and 
Ernst 2002). 
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Kavain was also found to be a smooth muscle relaxing agent on murine airway (60). An in 
vivo study, using a MPTP mouse model of Parkinson’s disease, demonstrated the efficacy 
of Kavain by reducing MPTP neurotoxicity, which may improve disease symptoms (61). 
In addition, Kavain was found to promote antithrombotic action on human platelets by 
suppressing COX which leads to TXA2 that eventually reduces platelet aggregation (62).  
     The pharmacokinetics and pharmacodynamics of Kavain revealed a maximum plasma 
concentration of 18 ng/ml following an oral dose of 200 mg D, L-Kavain with initial 
resorption time of 15 min and 1.8 h plasma reach peak point. Furthermore, the Kavain 
concentration in blood decreases with a half-life of 9 hours and distribution phase lasting 
from 3 to 5 hours (63). 
 
 
FIGURE 18: Urinary excretion of p-hydroxykavain after kavain oral uptake by hours as 
described (63). 
 
  
 22 
 
 
Kavain-dependent signaling pathway: 
     Current studies discovered that Kavain is a part of the TNF-a expression process by 
regulation of transcriptional factors including NF-kB (64). In addition, Kavain-chalcone 
and—lactone control on TNF-a-induced NF-kB activation in human Leukemia cells was 
introduced (31, 65). Lipopolysaccharide induced TNF-a activation factor (LITAF) is a 
transcription factor can control the TNF-a gene expression (66-68). Thus, compounds that 
inhibit the signaling of LITAF and led to a Kavain analog capable of inhibiting TNF-a 
secretion by down regulating LITAF were sought after. These efforts led to studies of this 
signaling pathway in vitro and in vivo. One study found that Kavain treatment deactivated 
LPS induced kinases like MyD88 and suppressed LITAF translocation in the cell nucleus. 
Kavain also reduced LPS induced production of many cytokines and kinases in vitro and 
in vivo, suggesting that Kavain plays a crucial role in the signaling pathway. Four different 
Kavain moderated kinase pathways are considered. The first pathway mechanism works 
by Kavain suppressing LPS-induced phosphorylation of MAPK, ERK 1/2 kinases. The 
second pathway: Kavain increases phosphorylation of kinases such as FAK, JNK without 
LPS response. The third pathway: Kavain is not involved in LPS-induced kinases 
phosphorylation like cJun, the fourth pathway: Neither Kavain nor LPS affects kinases like 
TAKI1 (34).  
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FIGURE 19/20: Proposed Kavain-related signaling pathways in response to LPS. Four 
Kavain-mediated kinase pathways are proposed. Pathway 1 (A): LPS-induced 
phosphorylation of kinases/factors is reduced by Kavain; Pathway 2 (B): Kavain 
treatment alone induces phosphorylation of kinases/factors; Pathway 3 (C): Kavain is not 
able to affect LPS-induced phosphorylation of kinases/factors; Pathway 4 (D): Some 
kinases/factors are not affected by either LPS or Kavain by (34). 
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Regulation of Kavain-mediated biological function: 
      A previous study explored Kavain-mediated biological functions, with a focus on 
distinguishing the molecular pathways involved with Kavain during the TNF-alpha 
regulation process. Several in vitro and in vivo experiments were used to determine these 
pathways. The process starts with the mitogen-activated protein kinases (MAPKs) which 
takes on major roles in intracellular signaling of different extracellular signal-regulated 
kinases (ERKs) that lead to TNF-alpha regulation. ERK2 specifically was found to be the 
potential kinase that is interacting with Kavain. Via ERK2 dephosphorylation, Kavain 
downregulates E. coli LPS, LITAF/TNF-alpha production. Other findings were gathered 
from these different studies. In vitro, Kavain significantly inhibited LPS-induced TNF-
alpha production in WT mouse primary macrophages and in LITAF-/- and ERK2-/- cells but 
with less effectiveness. Additionally, in vivo Kavain effect on wild type mice with CAIA 
was significant with small effects on ERK2-/- mice with CAIA. Furthermore, ERK2 showed 
more regulation by Kavain with no findings for ERK, which leads to the understanding of 
the ERK2 of being the main kinase for this process. Interestingly, overproduction of ERK2 
did not change NF-kB expression levels, which led to the hypothesis of Kavain can 
potentially inhibit other kinases like NF-kB. These findings show the clear association of 
Kavain as an inhibitor for LITAF/TNF-alpha production and ultimately as an anti-
inflammatory treatment for E. coli LPS-induced inflammatory diseases(33).  
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FIGURE 21: Analysis of TNF-α production after infection of viral particles in E. coli 
LPS/Kavain-treated cells as described (33). 
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KAV001 as a Kavain analogue was selected: 
    There were some concerns about Kavain safety after its discovery by the research 
community. Some data suggested that human use of Kavain extract may produce damaging 
effects on the developing CNS plus other aggravating side effects (69). 
  
 
FIGURE 22: 24 HOURS OF KAVAIN EXPOSURE PRODUCED SIGNIFICANT 
TOXICITY as described (Mulholland and Prendergast 2002). 
 
Since the Kavain clearance in the body is done by the liver, some indication of 
hepatotoxicity is reported (70). A different study found out that Kavain may induce adverse 
effects on liver (71). A safety report that was published to assess the safety of Kavain 
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concluded that available data is not enough to support the safety of Kavain (72). One of 
the reasons for this safety concern is because of Kavain metabolism by cytochrome P450 
in liver and excretion by the renal system which usually increases the likelihood of liver 
and kidney toxicity (52). Additionally, the hydrophobic nature of Kavain is a significant 
indicator of considerable toxicity occurrence (73, 74). 
 
 
FIGURE 23: The chemical activity of substance at solubility as described (Mayer and 
Reichenberg 2006). 
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     The main objective was therefore to design and synthesize a Kavain analog with more 
efficiency and safety. A Kavain analog showed an encouraging result in preventing and 
treating periodontitis in a mice model (75). An additional study using the same analog 
made a similar significant outcome in an arthritis murine model (76). Our previous data 
using the newly designed and synthesized Kavain analog that was named Kav001 resulted 
in superior anti-inflammatory and safety properties compared to Kavain both in vitro and 
in vivo (77). Specifically, this analog was shown to have anti-inflammatory properties in a 
LPS/P.gingivslis induced TNF-alpha model. The secondary objective was to explore the 
effect of Kav001 on different cytokines in different cell types such as THP-1 human cells, 
mouse raw cells, and different in vivo and in vitro study models. It was essential to see if 
this compound will have same effect on other important cytokines that have major roles in 
the host immune response (78, 79). During the inflammation process, any and all increases 
of proinflammatory cytokines levels should lead to the conclusion that any therapeutic 
approach should affect not only a specific cytokine but target also the rest of the major 
proinflammatory cytokines (80, 81). 
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FIGURE 24: Production of proinflammatory and anti-inflammatory cytokines as 
described (Gazivoda, Dzopalic et al. 2009). 
 
    Two major proinflammatory cytokines besides TNF-alpha are IL-1B and IL-6, which 
were thus chosen in investigating the efficacy of Kav001 (81, 82). Additionally, caspase-1 
is a key mediator for several essential cytokines during the inflammation process and was 
chosen as well. It is responsible for activating cytokines from the inactive form to the active 
and participating in cell death processes (83, 84).  Caspase-1 has multiple functions during 
inflammation (85), such as converting the cytokines from the inactive to the active form. 
After understanding caspase-1 functions, several studies explored the outcome of 
inhibiting caspase-1 levels, which introduced possible therapeutic applications (86-89).  
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FIGURE 25: Proatherogenic oxidized lipids induce higher caspase-1 activation in the 
larger sizes of HAECs than in smaller sizes of HAECs as described (Lopez-Pastrana, 
Ferrer et al. 2015). 
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Objectives: 
1. Investigate the safety and efficacy of Kav001 on some of the major inflammatory 
cytokines like TNF-a, IL-6 and IL-1b  
2. Examining the cytokines gene expression with Kav001. 
3. Investigating the effect of Kav001 on some inflammatory enzymes like Caspase-1.  
4. Record additional findings regarding the effective Kav001 dose on neutrophils 
infiltration.  
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MATERIALS AND METHODS 
Cells and Culture: 
- Mouse peritoneal macrophages. 
- Mouse bone marrow macrophages. 
- Mouse raw cells. 
- Human THP-1 cells. 
- RPMI-1640 culture medium (1X) [+] L-Glutamine (Cat#: 11875– 093, gibco by 
Life Technologies, Grand Island, NY). 
- 10% Fetal Bovine Serum, heat inactivated (Cat#: F4135-100ML, SIGMA-
ALDRICH, Saint Louis, MO).  
- 1% Penicillin-Streptomycin, 10,000 units penicillin and 10 mg streptomycin/ml 
(Cat#: P4333-100ML, SIGMA-ALDRICH, Saint Louis, MO). 
- Size 6 wells, sterile, tissue-culture treated (Cat#: SIAL0516, SIGMA-ALDRICH, 
Saint Louis, MO).  
- 0.25 % Trypsin-EDTA (1X) (Cat#: 252-056 100ML, gibco by Life Technologies, 
Grand Island, NY). 
- Dulbecco’s Phosphate Buffered saline (1X) [-] Calcium Chloride [-] Magnesium 
Chloride (Cat#:14190-144 500ML, gibco by Life Technologies, Grand Island, 
NY). 
- 37o C, 5% CO2 atmosphere incubator 
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Mice: 
- 8-10-weeks-old WT (C57BL/6) Mice (Jackson Labs). 
- The mice study was carried out in the Animal center facility located at Boston 
University Medical Campus under a pathogen-free condition unit. 
- The mice diet consisted of normal sterile food diet and water. 
- All animal protocols were approved by the Boston University Institutional Animal 
Care and Use Committee and were performed in compliance with the relevant 
animal care and use laws and institutional guidelines. 
 
ELISA: 
      Mouse raw cells, mouse peritoneal macrophages, bone marrow macrophages and 
human THP cells treated media were subjected to ELISA for TNF-a detection with the kit 
(Cat#: KMC30110, Invitrogen, Waltham, MA) or Bcl6 detection with the kit (KA2605, 
Abnova, St. Neihu District. Taipei City, Taiwan) or Human IL-B detection with the kit 
(Cat#: ab100562, Abcam, Cambridge, MA) or Human IL-6 detection with the kit (Cat#: 
KHC0061, Invitrogen, Waltham, MA) or Human TNF-a (Cat#: KHC3011, Invitrogen, 
Waltham, MA) or Mouse TNF-a (Cat#: EMTNFA, Thermo scientific, Frederick, MD). 
ELISA immunoreactivity was quantified using a microplate reader (Model 680, Bio-Rad, 
Portland, ME). The data were analyzed and then graphed using Microsoft Excel 2016 
(Microsoft corporation, Redmond, WA). 
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Western Blot Analysis: 
      Mouse bone marrow macrophages were treated with 100 ug/ml kavain as positive 
control or 100 ug/ml Kav001 as the negative control or co-treated with 0.1 μ g/mL LPS 
plus 100 μg/mL Kavain or plus 100 μ g/mL Kav001 for 36 hours. The proteins from each 
group were detected by Western blot according to the manufacturer's instructions. 
Antibodies were purchased from the following vendors: LITAF (611615, BD 
Biosciences, San Jose, CA) and actin (C-11, Santa Cruz Biotechnology, Santa Cruz, CA). 
 
Endotoxic Shock Assay: 
      Three Wild-Type mice at the age of 8 to 12 weeks with a matching weight between 
20 to 25g were injected intraperitoneally with 5*108 P.gingivalis/mouse. Following the 
injections, the mice were given by orally gavage 100μg/mouse Kavain or Kav001 or 100 
μl DMSO as control. The treated mice maintained a normal light cycle schedule with free 
access to rodent chow and water. The behavior and mortality rate were monitored and 
recorded hourly.  
 
Cytotoxicity tests: 
      A Cell Counting Kit-8 (CCK-8) assay (Dojindo Laboratories, Kumamoto, Japan) was 
used to measure the cytotoxicity of treated mouse peritoneal. First, the cell suspension 
(1x105 cell/well) done using a 96 well plate which is pre-incubated in a 37oC, 5% CO2 
incubator for 24 hours. A various concentration of 10 ul of the compounds were added to 
each plate and incubated for at least 6 hours. After adding the compounds, a 10 ul of 
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CCK-8 solution was added to each well and incubated for 1-4 hours. Using a microplate 
reader at 450 nm, absorbance measurements were taken.  
 
Collagen antibody induced arthritis (CAIA) mouse model: 
      All mice were pretreated with ArthritoMab (Cat# CIA-MAB-2C, MD Bioproducts, 
Middletown, MD) in the first day, and then three mice were oral gavaged with 100 μl 
DMSO as negative control group. As the positive control group, three mice were oral 
gavaged with 100 μl of 1X108 P.gingivalis (suspended in 2% Carboxymethyl Cellulose). 
As the test group, three mice were oral gavaged with 100 μl of 1X108 P.gingivalis and 
100 μg Kavain (dissolved in a 100 μl DMSO), and three mice were oral gavaged with 
100 μl of 1X108 P. gingivalis and 100 μg Kav001 (dissolved in a 100 μl PBS). All mice 
above were treated once/every Day until 12 days. Paws of mice were monitored for 
arthritis development daily for 12 days by scoring the redness and swelling of paws. The 
arthritis (paw) were imaged and further analyzed. The data were analyzed using paired t-
test with unequal variance using comparisons of control groups at each time point versus 
experimental groups. 
 
Neutrophil infiltration assay:  
      Mice (n=3) were untreated or treated by i.p. injection of E. coli LPS (1mg/kg body 
weight) and/or oral gavage of Kav001 (30mg/kg) for 24 hrs. Skin tissues from each group 
were taken and fixed in 4% paraformaldehyde, then embedded in O.C.T. compound) 
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(90). Skin sections (5 μm) were prepared, routinely stained with hematoxylin and eosin 
(H&E) and imaged. 
 
Cytokine array: 
      THP-1 cells in a 96-well plate at 1 × 105 cells per well were treated with 100µg/ml of 
E. coli LPS (Sigma) or plus 0.1mg/ml of Kav001 for 16 hrs at 37°C, 5% CO2. The 
conditioned medium was harvested and centrifuged at 1,500 × g to remove cell debris 
before being applied to a mouse protein cytokine array (RayBiotech, Norcross, GA). The 
array membranes were processed according to the manufacturer's instructions. Briefly, 
membranes were blocked with a blocking buffer, and then 1 ml of medium from each 
culture of treated cells was individually added and incubated at room temperature for 2 h. 
Finally, the results with immunoreactivity were assessed and quantified by using a 
VerSaDoc Imaging System, (Bio-Rad) and graphed. 
 
Statistical analysis: 
      All experiments were performed in triplicate and statistical analyses were conducted 
with the SAS software package. All data were normally distributed. For multiple mean 
comparisons, we conducted analysis of variance (ANOVA), while we used the Student's 
t-test for single mean comparison. For time-course study, we used a two-way repeated 
measure ANOVA. P values less than 0.05 were considered significant.   
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RESULTS 
Biochemical compound screening and Purity test: 
      Kavain have been found to inhibits P.gingivalis/LPS-induced TNF-alpha expression; 
therefore, the interest is in the medicinal chemistry and biochemical screening efforts to 
obtain selective analogs of Kavain with optimized bioactivity and physico-chemical 
properties. Inspection of the chemical structure of Kavain suggested that its lack of water 
solubility was likely due to absence of hydrophilic groups which led to design and 
synthesize about 10 Kavain analogs with one or more hydrophilic groups. Within a set of 
Kavain analogues, one analogue (named Kav001 with amino group, Figure 26) which can 
be synthesized in high yield with no O-acylation product detectable under H1-NMR 
spectroscopic analysis, and it is completely soluble in water after screening these analogs. 
Several commercially available kavain analogs like Baicalein and 4-Methoxy-benzoic acid 
were also been tested for efficacy and safety and used as positive control. 
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FIGURE 26: Biochemical screening of Kava Analogs. The chemical structure of 
compounds: Kavain as positive control (Santa Cruz), Baicalein as negative control 
(Sigma-Aldrich, CO.), 4-methoxybenzoic acid as negative control (Sigma-Aldrich, Co.), 
and Kav001 as test group (Karebay Biochem, Inc). 
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Toxicity assay: 
      Previously, demonstration showed that Kavain has a faint toxicity to cells probably due 
to its non-hydrophilic structure which might be the reason. Investigations with Kav001 
revealed that the water solubility of this compound indeed alleviated the Kavain-induced 
faint toxicity. As shown in Figure 27, treatment of mouse peritoneal macrophages with 
Kav001 for 4 h did not induce a significant toxicity as well as other soluble control 
compounds (4-methoxybenzoic acid or Baicalein) compared to Kavain treatment. Sample 
number three with kavain and LPS scored a survival percentage less than 85%. The positive 
control samples four and five had 95 % and 97 % respectively. However, sample number 
six with Kav001 and LPS scored a survival rate at 98% which is very significant in 
comparison with Kavain because of the KAV001 water solubility. 
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FIGURE 27: Toxicity assay. Mouse peritoneal macrophages were untreated as the 
negative control (No.1) and treated with LPS (0.1 μg/mL, No.2) as the positive control or 
co-treated with LPS plus variety of compounds, Kavain (No.3), 4-methoxybenzoic acid 
(No.4), Baicalein (No.5), or Kav001 (No.6) for 4h. The CCK-8 was then added into the 
cell media to incubate for 2hr and the absorbance at 450 nm was measured using a micro-
reader. The number of viable cells from each group was calculated and their survival rate 
was analyzed.   
 41 
 
 
Inhibition of LPS-induced TNF-a by ELISA: 
      An examination made to explore whether Kav001 inhibit LPS-induced TNF-α 
production in mouse peritoneal macrophages. As shown in Figure 28, treatment with 
Kav001 in mouse peritoneal macrophages reduced LPS induced TNF-α production to 14% 
(Figure 28A), which was more reduction than the corresponding Kavain treatment. 
Treatment of THP-1 cells by Kav001 also showed this specific reduction (Figure 28B) 
compared with the controls, indicating that Kav001 retained, and reflected the major 
biological functions of Kavain. 
 
 
FIGURE 28: Inhibition of LPS-induced TNF-α by ELISA. The mouse peritoneal 
macrophages or THP-1 cells were treated with DMSO as negative control or LPS (0.1 
μg/mL) as positive control, or co-treated with LPS plus 100 μg/mL of 4-Methoxybenzoic 
acid or Baicalein or Kav001 1 h. The supernatant medium from each group was collected 
and assessed by ELISA against TNF-alpha. 
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CAIA Animal model: 
 
      The biological function of Kav001 detected in vitro was further confirmed by an in 
vivo using CAIA mouse model. As shown in Figure 29, an abnormal swelling in the paws 
of mouse was clearly observed after treatment of P. gingivalis (II), however, P. gingivalis- 
induced swelling in the paws of mouse was significantly reduced after mice were oral 
gavaged with Kav001 (IV) in comparison to the positive control (II).
 
FIGURE 29:  CAIA animal model. WT mice pre-treated with ArthritoMab were 
gavaged with Kav001 as the negative control (I) or gavaged with P. gingivalis (II) as the 
positive control or co-gavaged with P. gingivalis plus Kavain (III), or with P. gingivalis 
plus 100 μg Kav001 (IV) as the test groups. Arthritis was monitored after treatment and 
histological effects of paws were analyzed after 10 days of treatments. Image of paws (I-
IV) was taken from each mouse (either control or treated mouse). Paw treated by DMSO 
alone (I) was assigned as the baseline; the actual value of others was compared relative to 
the baseline  
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Endotoxic shock: 
 
      To investigate whether Kav001 also functions as an antiendotoxic shock, mice were 
treated with a lethal number of P. gingivalis cells followed immediately by a tail vein 
injection of Kav001 (100 μg/100 μl/mouse) or other controls (same doses) and these mice 
were then monitored for their behavior and mortality every hour. The survival time of each 
treated mouse was measured and graphed (Figure 30). Three control mice (P. gingivalis 
alone) became sick at 5-10 min and deaths occurred between 30 and 35 mi. Treatment with 
Kav001 or Kavain delayed sickness and prolonged survival time by an average of 2 h 
compared to the control. This suggests thatKav001 provides treated mice with a significant 
resistance to P. gingivalis −induced endotoxic shock probably by inhibiting the subsequent 
rise in TNF-α after P. gingivalis treatment. 
 
FIGURE 30: Endotoxic shock. WT C57BL/6 mice were i.p. injected with P. gingivalis 
and oral gavaged with Kavain orKav001 or 100 μl DMSO as the negative control. Mice 
were then monitored and their status were recorded as the healthy (100% of survival), the 
distress (80%), the sick (60%), a serious sick (40%), the inability (20%), or the death (0%). 
P-value for the test groups (n = 3) was calculated by Wald's test in a discrete time hazard 
model using version 9.2 of SAS software. *One of three mice was dead but the rest were 
survivors after co-treatment of P. gingivalis plus 100 μg/mouse of Kavain.  
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Morphological characteristics of BMM cells: 
 
      It is known that mouse peritoneal macrophages will naturally change their shape such 
as extension of pseudopods after culturing for 3-5 days,12 and this rapid extension of 
pseudopods is believed to establish the immune needs. Present data (Figure 26-30 of the 
studies) showed that the treatment of mouse peritoneal macrophages with Kav001 inhibits 
P. gingivalis-induced inflammation/endotoxic shock, which led to hypothesize that 
Kav001 treatment of mouse peritoneal macrophages will induce extensive membrane and 
cytoskeleton remodeling such as pseudopods at early stage. To address this hypothesis, an 
observation was made regarding the change of shapes on BMM cell membrane after 
treatment of the cells with Kavain (B) or Kav001 (C) or untreated (A) as control. As shown 
in Figure 31, after treatment with Kav001 for 36 h, most cells (90%) extended their 
pseudopods (C) but only 45% for Kavain treated cells (B) and 5% for the untreated cells 
(A). 
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FIGURE 31: Observation of morphological characteristics of BMM cells. Pre-cultured 
mouse BMM cells were untreated as control (A) and treated with 100 μg/mL Kavain (B) 
or 100 μg/mL Kav001 (C) for 36 h. Photomicrographs were taken at Å~10 magnification. 
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Kav001 concentration in BMM cells: 
      In order to clarify the effects of Kav001 unit concentration on the formation of 
pseudopods extended from BMM, cells were untreated (A) as control or treated with 
different concentrations of Kav001 at 12.5μg/mL (B), 25μg/mL (C), 50μg/ml (D), or 
100μg/mL (E) for 36 h. Figure 32 shows that _50% of the cells initiated the formation of 
pseudopods after treatment with 50μg/mL Kav001 for 36 h. 
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FIGURE 32:  Effect of Kav001 unit concentration on the morphological characteristics 
in BMM cells. Pre-cultured mouse BMM cells were treated with MCSF alone as control 
(A) or with Kav001 at different concentration (μg/mL), 12.5 (B), 25 (C), 50 (D), or 100 
(E) for 36 h. Photomicrographs were taken at Å~10 magnification (left panel) or images 
in each box (left panel) were enlarged at Å~40 objective (right panel).  
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Bc16 ELISA analysis: 
      Some research groups (91, 92) indicate that factors such as LITAF and Bcl-6 may 
mediate pseudopod formation/ extension of macrophages. Therefore, we were interested 
in investigating the relationship between LITAF/Bcl3 and pseudopod formation in 
response to LPS/P.g. As shown in Figure 33A, both Kavain and Kav001 suppressed LPS-
induced LITAF expression. However, co-treatment of cells with LPS plus Kav001 induced 
Bcl6 production up to 220% when compared to the control (treatment with LPS alone, 
Figure 33B). These results suggest that Kav001 treatment of mouse BMM most likely 
drove their pseudopod formation via up-regulation of Bcl6 expression with simultaneous 
downregulation of LPS-induced LITAF expression. Since LITAF is well known as an 
important factor of TNF-α 2, the present data provide evidence for a supposed pathway 
connecting Kav001, LITAF, Bcl-6, pseudopod extension, and TNF-α-induced 
inflammation/disease upon P.g. infection/LPS stimulation in macrophages. 
 
 
 
 
 
 
 
 
 
 49 
 
 
 
FIGURE 33: ELISA analysis of Bcl6 in Kav001-treated BMM. A, Pre-cultured BMM 
cells were either untreated (No.1), treated with 100 μg/mL Kavain (No.2), with 100 
μg/mL Kav001 (No.3), with 0.1 μg/mL LPS (No. 4 & 6), co-treated with 0.1 μg/mL LPS 
plus 100 μg/mLKavain (No.5), or co-treated with 0.1 μg/mL LPS plus 100 μg/mL 
Kav001 (No.7) for 36 h. The proteins from each group were used for Western analysis 
with the antibody for LITAF (611615, BD Biosciences) or Actin (C-11, Santa Cruz 
Biotechnology). B, Pre-cultured mouse BMM cells were untreated with DMSO as 
control, treated with 100 ng/mL LPS, 100 μg/mL of Kavain, 4-Methoxybenzonic acid, 
Baicalein, Kav001, or cotreated 
with LPS plus Kavain, 4-Methoxybenzoic acid, Baicalein, or Kav001 as test group for 36 
h. The media from each group were collected and subjected to ELISA (anti-Bcl6). 
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Neutrophil infiltration essay: 
      As It is known that subcutaneous injection of LPS in mice induces neutrophil 
infiltration of tissues (93, 94) we are therefore interested in whether Kav001 treatment is 
able to suppress LPS-induced neutrophil infiltration. As shown in Fig.34, indeed, 
subcutaneous treatment of 30mg/kg of Kav001 significantly reduced LPS-induced 
Neutrophil infiltration of tissues in mouse (DI, II, III) compared to the positive control (CI, 
II, III). 
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FIGURE 34: Neutrophil infiltration assay. Mice (n=3) were untreated (A) or oral 
gavage-treated with 30mg/kg of KaV001 alone (B) as negative control or treated by i.p. 
injection of LPS (1mg/kg body) alone as the positive control (C) or co-treated with i.p. 
injection of LPS (1mg/kg body) plus oral gavage of Kav001 (30mg/kg) as test group (D) 
for 24 hrs. Skin tissues from each group were taken and fixed in 4% paraformaldehyde, 
then embedded in O.C.T. compound. Skin sections (5μm) were prepared, routinely 
stained with hematoxylin and eosin (H&E) and imaged. 
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Kav001-mediated inhibition of multiple cytokines: 
      In order to examine whether Kav001 also inhibits other cytokines besides TNF-α, we 
made a relevant experiment by ELISA. As shown in Fig.35, co-treatment of LPS plus 
Kav001 (A-C, #4) significantly reduces LPS-induced TNF-α, IL-1β, or IL-6 compared to 
the positive controls (A-C, #2). This phenomenon for detection of TNF-α was also 
observed while co-treatment of LPS plus Kavain but not be detectable for IL-1β or IL-6 
production (1B&C, #3). Additionally, Neither Kavain nor Kav001 was found to affect IL-
4. Our preliminary data indicate that Kav001 affects some cytokines in response to LPS, 
we are therefore interested in whether Kav001 is involved in other stimuli-mediated 
cytokines. As shown in Fig.36, Kav001 strongly reduced all three stimuli-induced cytokine 
productions, TNF-α (A, No.4), IL-1β (B, No.4), and IL-6 (C, No.4) compared to their 
positive control (No.2 of A, B, or C). This phenomenon for reduction of IL-1β (B, No.3) 
or IL-6 (C, No.3) was not observed while co-treatment of stimuli plus Kavain.  
      Since it is known that caspase 1 expression is activated with TNF-α, IL-1 beta, or IL-
6, then we want to further test whether Kav001 also inhibits caspase 1 caused by TNF-α, 
IL-1 beta, or IL-6. As shown in Fig.37, Kav001 (No.6) indeed reduced LPS-induced 
caspase 1 compared to the positive control (No.2). As control, Kavain not only did not 
reduce LPS-induced caspase 1, but increases its value (No.5).  
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FIGURE 35: ELISA analysis of cytokines in response to various stimuli. THP-1 cells 
were untreated as control (A-C, #1) or treated with 5ng/ml TNF-α (A, No.2-4), 10ng/ml 
IL-1β (B, No.2-4), or 10ng/ml IL-6 (C, No.2-4), plus with 100 µg/ml of Kavain (A-C, 
No.3) or plus 100µg/ml Kav001 (A-C, No. 4) for 2 hrs. Cells were then washed with PBS 
and cultured overnight. The supernatant medium from each group was assessed by 
ELISA against TNF-α (A), IL-1β (B), or IL-6 (C). 
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FIGURE 36: ELISA analysis of caspase 1. THP-1 cells were untreated (No.1) or treated 
with 100µg/ml Kavain (No.3),100µg/ml Kav001 (No.4), 0.1µg/ml LPS (No.2) as positive 
control, or co-treated with LPS plus Kavain (No.5) or plus Kav001 (No.6) o/n. The 
supernatant medium from each group was collected and assessed by ELISA against 
caspase 1. 
 
FIGURE 37: ELISA analysis of caspase 1. THP-1 cells were untreated (No.1) or treated 
with 100µg/ml Kavain (No.3),100µg/ml Kav001 (No.4), 0.1µg/ml LPS (No.2) as positive 
control, or co-treated with LPS plus Kavain (No.5) or plus Kav001 (No.6) o/n. The 
supernatant medium from each group was collected and assessed by ELISA against 
caspase 1.   
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Cytokine array: 
      In order to analyze whether the treatment of Kav001 affects any kinases/protein as 
upstream factor of caspase 1 in response to LPS, a kinase/protein array was performed. As 
shown in Fig. 38 B & C, Kav001 significantly reduced LPS-induced kinases such as Akt 
(Protein kinase B) at 17%, ATM (Ataxia telangiectasia mutated) at 13%, caspase 3 at 
11.5%, caspase 7 at 8.6%, CHK1 (Checkpoint kinase 1) at 26.4%, CHK2 (Checkpoint 
kinase 2) at 15.3%, ERK1/2 at 12.7%/14.8% but does not affect p27, p53, or TAK1 
(Transforming growth factor beta-activated kinase 1).   
 
FIGURE 38: Kinase/Protein array. (A) The stamped identification number on the array. 
(B) THP-1 cells were untreated or treated with LPS alone or LPS+ Kav001 overnight. 
The conditioned medium from each test group was assessed by protein assay and 
quantified by a VerSaDoc Imaging System. (C) Analysis of the intensity on the array 
filter.  The intensity of each test kinase/protein from LPS alone-treated cells was assigned 
to a base value (100%). The density of other protein induced by test groups was 
compared to the base value. There ratio was calculated in this table. 
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DISCUSSION 
      To obtain analogs with optimized scaffolds of Kavain, each analogue's structure was 
designed with one or two different hydrophilic side chains containing OH or N moieties to 
provide alterations of the main chemical structure of Kavain (C14H14O3). Consequently, 
most of these analogs showed good solubility in water/aqueous medium and did not induce 
significant toxicity to mouse peritoneal macrophages as compared with the positive control 
(treated with Kavain, data not shown). However, among these analogs, Kav001 
(C13H22O5N, with similar function to Kavain or better) showed a significant inhibition of 
TNF-α production in response to P. gingivalis/LPS stimulation. In order to determine 
whether the solubility helps Kav001 to increase its biological function, Kav001 was 
dissolved in either water or DMSO, and then a variety of tests was performed. Finally, 
Kav001 dissolved in water is more effective than in DMSO, but water-dissolved Kav001 
does not show more sustained efficacy if the time for treatment is 2 days or longer (data 
not shown). Thus, for a long-time test (48 h) the multiple treatments (one treatment/day 
until 2 days or more days) of water-soluble Kav001 may be required. In addition, Kav001 
has a slightly different chemical structure than Kavain but shows stronger inhibition of 
TNF production than other analogs including Kavain. This suggests that the specific 
structural changes of Kav001 are responsible for its biological function in the inhibition of 
TNF production. Future investigations will evaluate the role of Kav001 chemical structure 
and structure-function relationship in more detail. 
      Additionally, the treatment of mouse peritoneal macrophages with Kav001 showed a 
stronger inhibition of LPS-induced-TNF-α production than treatment with Kavain. 
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Observation revealed that the same phenomenon in RAW cells (mouse macrophage-like 
cells). However, in THP-1 cells (human monocyte-like cells), the inhibition of TNF-α 
production by Kav001 was weaker than that of Kavain. This latter observation with THP-
1 cells may be due to the fact that we had the THP-1 cells in suspension at the time of drug 
treatment, that is, THP-1 cells were not adhering the plate by PMA before the treatment. 
Whilst both mouse peritoneal macrophages and RAW cells were treated after the cells were 
attached to the culture dish, suggesting that the soluble Kav001 may work better on adhered 
cells than cells in suspension. 
      Treatment of mouse peritoneal macrophages with P. gingivalis or stimulant such as 
LPS leads to rapid generation of pseudopods with an increase of Bcl6 production. This 
phenomenon appears to reflect the natural corresponding immune response. However, we 
have observed that some mouse peritoneal macrophages also extend their pseudopods after 
4-5 days culturing in the regular medium without Bcl6 induction. Interestingly, treatment 
of cells by Kav001/Kavain also induces mouse macrophage pseudopods only for 36 h with 
Bcl6 production. 
      Our previous data found that LITAF regulates TNF-α and the treatment of Kavain in 
macrophages suppresses LITAF/TNF-α in response to LPS. The results show that Kav001, 
a compound with modified chemical structure of Kavain, was selected due its optimized 
biological activity of inhibiting TNF-α expression. Occasionally, we found that the 
treatment of Kav001 also extended the pseudopods in BMM cells faster than the control. 
We are therefore interested in an explanation of observed phenomena. According to one 
research group, both LITAF and BCL6 are involved in this cell morphology with opposite 
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expressions. Another research group discovered that the numbers of pseudopodia per cell 
in Bcl6+/+ BMM are more than in Bcl6−/− BMM.15 Thus, we hypothesize that an increase 
in pseudopodia and its following extension in BMM will be dependent on either the 
suppression of LITAF or expression of Bcl-6. Our present results are consistent with this 
hypothesis. This suggests that Kav001 treatment immediately activates its immune system, 
protecting the host cells/mice from P.g infection and LPS-induced TNF-α 
production/inflammation/ disease by induction of Bcl6, reduction of LITAF expression, 
and the formation/extension of its pseudopod. 
      Kavain was found to affect TNF-α transcriptional regulation (33) To obtain the 
optimized scaffolds of Kavain, we had designed, synthesized and examined some Kavain 
analogs and finally found a better one, Kav001. Treatment of Kav001 in cells such as 
mouse RAW cells or human monocyte-like cells (THP-1) showed reduction of LPS-
induced TNF-α production. Compared with Kavain, Kav001 has stronger biological 
function in vitro and in vivo experiments such as CAIA, or Endotoxic Shock, suggesting 
that Kav001 obtains optimized bioactivity and physico-chemical property with a modified 
chemical structure of Kavain. In this paper, we further found that Kav001 not only inhibits 
LPS-induced Neutrophil infiltration, but also IL-1β, IL-6 or caspase 1.  
      DMSO is known to be widely used as reagent solvent but sometimes causes a little 
toxic to mammalian cells (95) It is known that Kavain is dissolved in the higher 
concentration of DMSO (≥25%) while Kav001 is completely dissolved in water. This 
water-soluble property may be the reason why Kav001 prevent itself from DMSO-
mediated toxicity cells with a longer period of efficacy. Our most recent data support this 
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potential hypothesis Regarding the mount of compound used in the treatment of mice, we 
selected oral garage with more dosage of compound rather than i.v. or i.p. injection. It is 
because of 1) easy processing, 2) repeatability, 3) stability (for example, a careless or an 
inappropriate treatment of mice by i.v. injection sometimes causes the serious injuries or 
death of mice, that affects correctly collection/analysis of data from in vivo experiments 
such as neutrophil infiltration).   
      Additionally, neutrophils are key components of the innate immune response and 
neutrophil infiltration of tissues contribute to the pathogenesis of inflammatory diseases 
(92, 96) (97) In order to suppress the neutrophil infiltration induced by tissue injury (brain 
injury, I/R injury, ethanol feeding-induced liver injury, or LPS stimulation, a variety of 
specific inhibitors such as Clenbuterol, PAI-1 (Plasminogen activator inhibitor-1), MgIG 
(Magnesium isoglycyrrhizinate), or Phillyrin have been widely studied. Also, researcher 
groups have suggested that these inhibitors suppress neutrophil infiltration probably via 
regulation of some factors such as MyD88 or p38 MAPK (97-102). However, these studies 
remain questions. Namely, the same is to inhibit the neutrophil infiltration, but it is unclear 
whether there is a common key point between their pathways. Our data here also show that 
the treatment of Kav001 significantly reduces LPS-induced neutrophil infiltration. Since 
our previous data (33, 34) show that MyD88/LITAF is involved in Kavain-mediated 
signaling pathway, we hypothesize that the neutrophil infiltration of cells or mice may go 
through a similar pathway induced by even different inhibitors. If this is potential 
hypothesis, Kav001 may be used for suppression of neutrophil infiltration induced by other 
different stimuli or injury.  
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      It is known that TNF-α, IL-1β, or IL-6 expression is elevated in several inflammatory 
diseases including RA, systemic juvenile idiopathic arthritis, systemic lupus 
erythematosus, ankylosing spondylitis, psoriasis or Crohn's disease. The studies show that 
blockade of these cytokines is effective at prevention and treatment in the cytokine-induced 
models of inflammatory diseases (103-108). Since TNF-α, IL-1β, or IL-6 was found here 
to be inhibited by Kav001, we assume that Kav001 may have treatment for diseases caused 
by these cytokines. 
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CONCLUSION 
      Our present data show that the treatment of Kav001 significantly inhibits P.g.-induced 
CAIA/Endotoxic shock. Most recently, we found that Kav001 also suppresses P.g.- 
induced the neutrophil infiltration of tissues. Neutrophils are key components of the innate 
immune response and contribute to the pathogenesis of inflammatory diseases. In order to 
suppress neutrophil infiltration induced by tissue injury (brain injury), I/R injury, ethanol 
feeding-induced liver injury, or LPS stimulation, a variety of specific inhibitors such as 
Clenbuterol, PAI-1 (Plasminogen activator inhibitor-1), MgIG (Magnesium 
isoglycyrrhizinate), or Phillyrin have been widely studied. Although these studies show 
several possible methods of inhibiting neutrophil expression, it is unclear whether there is 
a common pathway uniting all of them. Thus, we hypothesize that the suppression of 
neutrophil infiltration in cells/tissues by different inhibitors may go through a similar 
pathway. If this is a potential hypothesis, Kav001 may be used as a key inhibitor to suppress 
the neutrophil infiltration induced by other stimuli or injury. It is known that TNF-α, IL-
1β, or IL-6 expression is elevated in several inflammatory diseases including RA (as 
mentioned above), systemic juvenile idiopathic arthritis, systemic lupus erythematosus, 
ankylosing spondylitis, psoriasis or Crohn's disease. The previous studies show that 
blockade of these cytokines is effective at prevention and treatment in the cytokine-induced 
models of inflammatory diseases. Since TNF-α, IL-1β, and IL-6Kav001 was found here to 
be inhibited by Kav001, we assume that Kav001 may have treatment for diseases caused 
by these cytokines. We will try to address this hypothesis for our future research. 
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